Compare PRCH & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCH | GLUE |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 962.0M | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | PRCH | GLUE |
|---|---|---|
| Price | $8.48 | $23.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $17.56 | ★ $29.50 |
| AVG Volume (30 Days) | 1.3M | ★ 2.7M |
| Earning Date | 02-24-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.27 | 0.25 |
| Revenue | ★ $442,483,000.00 | $181,538,000.00 |
| Revenue This Year | N/A | $84.02 |
| Revenue Next Year | $17.06 | N/A |
| P/E Ratio | ★ $31.37 | $93.93 |
| Revenue Growth | N/A | ★ 1112.27 |
| 52 Week Low | $3.72 | $3.50 |
| 52 Week High | $19.44 | $25.77 |
| Indicator | PRCH | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 35.35 | 67.65 |
| Support Level | $9.09 | $23.16 |
| Resistance Level | $9.97 | $24.49 |
| Average True Range (ATR) | 0.47 | 1.54 |
| MACD | 0.02 | 0.53 |
| Stochastic Oscillator | 6.75 | 83.03 |
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has two reportable segments: The vertical Software segment provides software and services to home services companies. The Vertical Software segment software and services provide inspection, mortgage, and title companies on a subscription and transactional basis, several key businesses, including inspection software and services, title insurance software, mortgage software, moving services, mover and homeowner marketing, and measurement software for roofers. The insurance segment provides consumers with insurance and warranty products to protect their homes, earning revenue through premiums collected on policies, policy fees, and commissions. Majority revenue is from Insurance segment.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.